Skip to content

Adults with Active Psoriatic Arthritis and Obesity

NO LONGER ACCEPTING APPLICATIONS
Published on:
October 17, 2024
Sign-up Expiration:
Updated:
Topics:
Locations:

The study aims to evaluate the efficacy and safety of Ixekizumab and Tirzepatide at the maximum tolerated dose in adult participants with active psoriatic arthritis and obesity. The primary endpoint is simultaneously achieving ACR50 and at least 10% weight reduction.

View Additional Information
View Clinical Trial Attachment
Sign Up NowExpired - View Other Trials
ENDED